SIRT1 inhibition in pancreatic cancer: Contrasting effect in vitro and in vivo

Abstract:

Gemcitabine remains the cornerstone for pancreatic cancer treatment, although most patients become resilient to the therapy. Up-regulated in pancreatic cancer, Sirtuin 1 (SIRT1) is involved in tumorigenesis and drug resistance through deacetylation of downstream targets. However the mechanism through which SIRT1 regulates drug sensitivity in cancer cells is largely unknown.  In this seminar, Dr Chern will be sharing with us her investigation on the role of SIRT1 in mediating chemosensitivity in pancreatic cancer models in vitro and in vivo.

Speaker's Profile:

Dr Oon Chern Ein did her BSc (1st Class Hons) in Biotechnology at Universiti Kebangsaan Malaysia before securing a scholarship from the Ministry of Higher Education Malaysia to further her doctorate studies in Medical Oncology in University of Oxford, United Kingdom. She then trained in Karolinska Institutet, Sweden as a postdoctoral fellow before returning to Malaysia to serve as a senior lecturer at Institute for Research in Molecular Medicine, Universiti Sains Malaysia. She was the proud recipient of the Ranjeet Bhagwan Singh Medical Research Trust Fund (2014), the Exiqon Young Scientist Award-South East Asia (2014) and Loreal-UNESCO for Women in Science (2015). Chern was also selected by the Council for the Lindau Nobel Laureate Meetings to participate in the 65th Lindau Nobel Laureate Meeting in Germany in 2015.  She was recently awarded the ICRETT Fellowship by Union for International Cancer Control to establish collaboration with Nanyang Technological University Singapore. Her area of research includes understanding the molecular interactions between cancer cells and the tumour microenvironment which contribute to tumour progression and therapeutic failures.